CD19 and acute lymphoblastic leukemia: Response rates and outcomes were significantly improved in patients with relapsed/refractory BCP ALL by treatment with the CD22-directed toxin-conjugated monoclonal antibody, inotuzumab-ozogamicin or the CD19-directed, T cell-engaging bispecific antibody, blinatumomab [2,3].